Please assess the completion status of the following clinical trial:

Trial Title: Magnetic Seizure Therapy for Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. DSM-5 diagnosis of schizophrenia;~2. convulsive therapy clinically indicated, such as severe psychomotor excitement or retardation, attempts of suicide, being highly aggressive, pharmacotherapy intolerance, and ineffectiveness of antipsychotics;~3. the positive and negative syndrome scale (PANSS)\[20\] score ≥ 60;~4. informed consent in written form.~Exclusion Criteria:~1. diagnosis of other mental disorders;~2. severe physical diseases, such as stroke, heart failure, liver failure, neoplasm, and immune deficiency;~3. present with a laboratory abnormality that could impact on efficacy of treatments or safety of participants;~4. failure to respond to an adequate trial of ECT lifetime;~5. are pregnant or intend to get pregnant during the study;~6. other conditions that investigators consider to be inappropriate to participate in this trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- magnetic seizure therapy (Type: EXPERIMENTAL): 10 treatment sessions of MST, three times per week in the first two weeks, two times per in the following two weeks.
- electroconvulsive therapy (Type: ACTIVE_COMPARATOR): 10 treatment sessions of modified-ECT, three times per week in the first two weeks, two times per in the following two weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).